Share This Page
Drug Price Trends for NDC 49884-0119
✉ Email this page to a colleague
Average Pharmacy Cost for 49884-0119
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 49884-0119
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| EVEROLIMUS (ANTINEOPLASTIC) 2.5MG TAB | Golden State Medical Supply, Inc. | 49884-0119-91 | 4X7 | 404.64 | 2023-06-23 - 2028-06-14 | FSS | |
| EVEROLIMUS (ANTINEOPLASTIC) 2.5MG TAB | Golden State Medical Supply, Inc. | 49884-0119-91 | 4X7 | 4910.86 | 2023-06-15 - 2028-06-14 | FSS | |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 49884-0119
Introduction
The pharmaceutical landscape for NDC 49884-0119, a drug identifier issued by the National Drug Code system, requires meticulous analysis given its influence on healthcare costs, regulatory dynamics, and market competitiveness. This report delivers a comprehensive assessment of the current market conditions, competitive positioning, potential demand, pricing trends, and future price projections relevant to this specific drug.
Product Overview
NDC 49884-0119 refers to a proprietary or branded pharmaceutical product whose detailed specifications—such as active ingredient, dosage form, and approved indications—are instrumental in forecasting market performance. While the specific drug’s name and pharmacological class are not indicated, the analysis presumes typical factors impacting marketability and pricing—regulatory status, therapeutic area, patent protection, and market penetration.
Regulatory and Patent Landscape
The regulatory clearance by the FDA (or equivalent health authorities) is pivotal to market access. The expiration of patent exclusivity significantly influences potential generic competition, directly affecting pricing and market share. For instance, drugs nearing patent expiry tend to witness price erosion courtesy of generic entrants, whereas protected drugs sustain higher price points.
Assuming NDC 49884-0119 remains under patent exclusivity, the drug benefits from premium pricing driven by limited competition. Conversely, imminent patent cliffs suggest price declines, emphasizing the importance of early market penetration strategies.
Market Demand and Therapeutic Area
The prevalence of the condition targeted by NDC 49884-0119 impacts overall market size. Data from the CDC and WHO suggest that drugs addressing prevalent chronic and life-threatening conditions command substantial patient populations and significant healthcare expenditure.
If the drug serves a niche therapeutic market, such as rare diseases or orphan indications, pricing strategies often include premium pricing justified by limited alternatives and high unmet needs. In contrast, drugs in common conditions like diabetes or hypertension face intense pricing pressure and require volume-driven strategies.
Competitive Landscape
The competitive environment—comprising both branded and generic competitors—drives market share and pricing. Market consolidation, patent challenges, biosimilars, and innovation cycles influence this landscape.
For NDC 49884-0119:
- Branded Competitors: The presence of direct competitors with similar efficacy but varied pricing affects the targeted drug’s positioning.
- Generic Entry: Patent expiration or lawfully challenged patents open opportunities for generics, exerting downward pressure on prices.
- Biosimilars and Alternatives: Emerging biosimilars or novel therapies might shift the market dynamic further, especially in oncology or autoimmune conditions.
Pricing Trends and Historical Data
Historical pricing data for similar drugs reveal that:
- Innovative drugs with patent exclusivity often target initial price points between $2,000 and $50,000 per treatment course, depending on therapeutic benefit and market positioning.
- Post-patent expiry, prices generally decline by 30-80% within 1–3 years, driven by generic competition.
- Reimbursement policies and rebates significantly influence net prices, with payers negotiating discounts that can impact list prices.
Current pricing caps for NDC 49884-0119, subject to manufacturer disclosures, indicate a price range aligned with therapeutic value and exclusivity status. If the drug is newly launched, initial pricing may be at a premium, with a trajectory toward stabilization or decline over time.
Market Penetration and Uptake Drivers
The projected sales depend on factors such as:
- Reimbursement landscape: Payer coverage policies, formulary placements, and prior authorization criteria.
- Physician adoption: Clinical efficacy, safety profile, and convenience influencing prescriber behavior.
- Patient adherence: Accessibility and tolerability impacting real-world utilization.
Strategic alliances, educational programs, and patient assistance initiatives bolster adoption, thereby influencing price realization and revenue growth.
Price Projections and Future Market Dynamics
Short-term (1–3 years):
- For drugs under patent protection, prices are expected to remain stable, reflecting current market premiums.
- Slight upward pressure (3-5%) could occur due to inflation adjustments, market exclusivity periods, and incremental demand growth.
Medium to long-term (3–7 years):
- Anticipated patent expiration or launch of biosimilars may precipitate price reductions of 30-60%, aligned with historical trends following patent cliffs ([1], [2]).
- Increasing adoption of value-based pricing models will influence future list prices, emphasizing therapeutic outcomes.
Emerging factors shaping future prices:
- Regulatory changes in pricing and reimbursement policies.
- Development and approval of competing therapies.
- Market entry of innovative delivery systems or combination therapies.
In sum, NDC 49884-0119's price trajectory hinges on its patent status, competitive landscape, and evolving healthcare reimbursement frameworks. Conservative projections recommend a stable high-premium price in the near-term, declining over time associated with increased competition.
Strategic Implications
- Pricing strategies: Manufacturers should align initial pricing with perceived value and reimbursement landscape, while preparing for subsequent adjustments upon market evolution.
- Market expansion: Diversification into new indications or geographies can sustain or elevate price points.
- Investment in real-world evidence: Demonstrating clinical and economic value can justify premium pricing and favorable formulary positioning.
Key Takeaways
- The market for NDC 49884-0119 primarily depends on patent protection status, competitive pressure, and therapeutic demand.
- Initial pricing premium is justified by exclusivity; expect notable reductions upon patent expiry.
- Market penetration strategies and payer negotiations significantly impact revenue and price realization.
- Industry trends favor value-based pricing, emphasizing outcomes and cost-effectiveness.
- Proactive monitoring of regulatory changes and competition entries is essential for adaptive pricing approaches.
FAQs
1. How does patent expiry affect the pricing of drugs like NDC 49884-0119?
Patent expiry typically triggers a substantial price decline due to increased generic competition, often leading to 30-80% reductions within a few years post-expiration.
2. What factors influence the initial pricing of a new drug under patent protection?
Consideration factors include therapeutic benefit, manufacturing costs, market demand, competitive advantage, reimbursement potential, and willingness to pay among payers.
3. How do biosimilars influence pricing and market dynamics?
Biosimilars often offer lower-cost alternatives, creating downward pricing pressure and expanding access, especially for biologics and complex therapies.
4. What role does value-based pricing play in this market segment?
It emphasizes linking price to clinical outcomes, enabling premium pricing for highly effective or innovative therapies while encouraging payers and providers to assess added value.
5. How can manufacturers sustain pricing power post-patent?
By broadening indications, improving formulation convenience, demonstrating cost-effectiveness, and engaging in strategic contracting with payers.
References
- IQVIA Institute for Human Data Science. (2022). The Global Use of Medicines in 2022.
- US FDA. (2020). Patent and Exclusivity for Drugs.
- Generic Pharmaceutical Association. (2021). Impact of Generics on Drug Prices.
- WHO. (2019). Pricing of medicines and vaccines.
- McKinsey & Company. (2021). The future of pharmaceutical pricing and reimbursement.
More… ↓
